How do sodium‑glucose co‑transporter‑2 (SGLT2) inhibitors affect longevity in adults with type 2 diabetes, heart failure with reduced ejection fraction, or chronic kidney disease?

SGLT2 Inhibitors Significantly Extend Longevity in High-Risk Populations

SGLT2 inhibitors substantially reduce all-cause mortality and should be strongly recommended for adults with type 2 diabetes who have established cardiovascular disease, heart failure with reduced ejection fraction, or chronic kidney disease—particularly those at high or very high risk of disease progression. 1

Mortality Benefits Across Disease States

Chronic Kidney Disease Populations

The most compelling longevity data comes from patients with CKD, where risk-stratified benefits are clearly defined:

• Very high-risk CKD patients: SGLT2 inhibitors reduce all-cause mortality by 48 fewer deaths per 1000 patients over 5 years (high certainty evidence), representing approximately a 15% relative risk reduction 1

• High-risk CKD patients: 24 fewer deaths per 1000 patients (moderate certainty evidence) 1

• These mortality benefits apply regardless of diabetes status—the recommendations explicitly state they are "applicable to all adults with CKD, irrespective of type 2 diabetes status" 1

Cardiovascular Disease and Heart Failure

For patients with established cardiovascular disease or heart failure:

• SGLT2 inhibitors reduce all-cause death with a relative risk of 0.85 (95% CI 0.78-0.94) based on 44,397 participants 2

• Cardiovascular death is reduced with a relative risk of 0.83 (95% CI 0.74-0.93) 2

• In older or frail patients with type 2 diabetes and heart failure, SGLT2 inhibitors reduce total mortality (RR 0.81,95% CI 0.69-0.95) and cardiac death (RR 0.80,95% CI 0.69-0.94) 3

Cardiovascular and Kidney Protection Contributing to Longevity

Beyond direct mortality reduction, SGLT2 inhibitors extend longevity through prevention of life-threatening complications:

Cardiovascular Events

• Heart failure hospitalization: 70% relative risk reduction (RR 0.70,95% CI 0.62-0.79), preventing 25-30 hospitalizations per 1000 patients in very high-risk groups 1, 2

• 3-point MACE (cardiovascular death, MI, stroke): 11% relative risk reduction (RR 0.89,95% CI 0.81-0.98) 2

• 4-point MACE: 18% relative risk reduction (RR 0.82,95% CI 0.70-0.96) 2

Kidney Protection

• Kidney failure prevention: 30% relative risk reduction (RR 0.70,95% CI 0.62-0.79), preventing 58 cases per 1000 very high-risk patients over 5 years 1, 2

• Composite kidney outcomes: 32% relative risk reduction (RR 0.68,95% CI 0.59-0.78) 2

• Kidney protection is critical for longevity since end-stage kidney disease dramatically increases mortality risk 1

Clinical Implementation Algorithm

Step 1: Identify Eligible Patients

Initiate SGLT2 inhibitors (canagliflozin, dapagliflozin, or empagliflozin) in patients with type 2 diabetes who have ANY of the following 1:

• Established cardiovascular disease: Prior MI, stroke, revascularization, >50% arterial stenosis, cardiac ischemia on stress testing, or left ventricular hypertrophy

• Heart failure with reduced ejection fraction: Regardless of diabetes status 1, 4

• Chronic kidney disease: eGFR 25-60 mL/min/1.73m² OR urine albumin/creatinine ratio >200 mg/g (or ≥3 mg/mmol) 1

Step 2: Risk Stratify CKD Patients

Use KDIGO classification based on eGFR and albuminuria 1:

• Very high risk: eGFR <30 mL/min/1.73m² with any albuminuria, OR eGFR 30-44 with albuminuria ≥30 mg/mmol → Strong recommendation for SGLT2 inhibitor 1

• High risk: eGFR 30-44 with albuminuria 3-30 mg/mmol, OR eGFR 45-59 with albuminuria ≥30 mg/mmol → Strong recommendation 1

• Moderate/low risk: Other CKD combinations → Weak recommendation in favor 1

Step 3: Initiate Treatment

• Start SGLT2 inhibitor independent of current HbA1c level or glycemic control 1

• Do not wait to optimize other therapies first—these decisions should be made "independent of background therapy" 1

• Generally avoid new initiation if eGFR <20 mL/min/1.73m², though continuation below this threshold is acceptable until dialysis 1

Critical Caveats

Populations Lacking Evidence

The longevity benefits may not apply to 1:

• Patients already on dialysis or kidney replacement therapy
• Kidney transplant recipients
• Polycystic kidney disease
• Rare kidney diseases (>150 conditions)
• Very elderly (≥65 years may have overestimated risk)
• Very young (<40 years may have underestimated risk)

Safety Considerations

SGLT2 inhibitors have a favorable safety profile with 2, 5:

• Reduced hypoglycemia compared to placebo (RR 0.93,95% CI 0.89-0.98)
• Reduced severe hypoglycemia requiring assistance (RR 0.75,95% CI 0.65-0.88)
• Increased risk of genital and urinary tract infections (manageable)
• No significant increase in diabetic ketoacidosis, acute kidney injury, amputation, or fracture risk in most studies 2, 3, 5

Mechanisms Supporting Longevity

The longevity benefits likely result from multiple mechanisms 6, 4:

• Improved β-cell function through reduction of glucotoxicity
• Reduced insulin resistance and increased insulin sensitivity
• Increased diuresis and reverse cardiac remodeling
• Altered intrarenal hemodynamics providing renoprotection
• Cardioprotective effects independent of glucose lowering

Ancillary Longevity Benefit: Diabetes Prevention

In patients with cardiovascular or kidney disease but without diabetes, SGLT2 inhibitors reduce new-onset diabetes by 26-33% 7, which may contribute to long-term longevity by preventing diabetes-related complications.